SUBSCRIBE
SUBSCRIBE
News   Drug Development

Onyx Pharmaceuticals, Inc. Says FDA Agrees on Blood Cancer Drug Trial Design

February 2, 2010 | 
1 min read
Reuters -- Onyx Pharmaceuticals Inc said it reached an agreement with the U.S. Food and Drug Administration on the design of the late-stage trial of its blood cancer drug.
Clinical research Phase III
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Pictured: Entrance to Pfizer's office in Belgium
Breast cancer
Pfizer Builds Case for Tukysa as ‘New Standard Regimen’ in First-Line Metastatic Breast Cancer
December 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Roche Diagnostics building in California
Breast cancer
Roche’s Oral SERD Cuts Death Risk by 30% in Early-Stage Breast Cancer
December 11, 2025
 · 
2 min read
 · 
Tristan Manalac
IN PARTNERSHIP WITH ANAPTYSBIO
Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment
December 11, 2025
 · 
1 min read
 · 
Jennifer Smith-Parker
Podcast
Weight Loss Waves, Pazdur’s Exit and FDA Instability, New Neuro Breakthroughs
December 10, 2025
 · 
1 min read
 · 
Heather McKenzie